ITOS (iTeos Therapeutics) Short-Term Debt to Capital
The market trend for iTeos Therapeutics (ITOS) shares demonstrates the 0.00 indicator. The company's revenues are based on the development of cancer therapies and payments from its strategic partner GSK. High competition in the patent landscape creates risks of losing market position. Meanwhile, the business relies on external research centers, controlling test quality through strict regulatory oversight by management.
Analytical breakdowns for iTeos Therapeutics
- stock quotes and analyst forecast:
- business market valuation indicators:
- book capitalization information:
- company liabilities and liquidity data:
Total Debt to Capital iTeos Therapeutics|ITOS - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio iTeos Therapeutics, Inc.|ITOS - Aggregate Debt Obligations|Debts to Book Capitalization iTeos Therapeutics Inc|ITOS - Long-Term Debt Volume|Company Short-Term Debt iTeos Therapeutics|Quick Liquidity iteostherapeutics.com
- company profitability and valuation multiples indicators:
Fundamental valuation:iTeos
This metric measures the company's reliance on obligations with maturities of up to one year relative to its equity, allowing investors to differentiate a strategic liquidity reserve from stagnation via the dynamics of the short-term debt-to-equity structure, which is critical for iTeos Therapeutics (ITOS), whose viability during clinical trials without commercial revenue relies entirely on the remnants of past partnership payments.
Main competitors
Short-Term Debt to Capital ARGX|BNTX (BioNTech Pharma) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ABVX (Abivax Pharma)|Short-Term Debt to Capital admabiologics.com ADMA|PTGX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital IMVT (Immunovant Inc)|Kiniksa Pharmaceuticals Ltd (KNSA) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Grifols Biemat|ADPT (Adaptive Biotechnologies) - Short-Term Debt to Capital|Short-Term Debt to Capital celldex.com|Short-Term Debt to Equity Ratio AUPH (Aurinia Pharmaceuticals Inc.)|BCRX (BioCryst Pharmaceuticals, Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VERA (Vera Pharma)|Short-Term Debt to Capital Coefficient Dianthus Corp (DNTH)|PHVS - Short-Term Debt to Equity|AbCellera Biologics Inc (ABCL) - Short-Term Debt to Equity Ratio|Tourmaline Bio (TRML) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Precigen Inc|Short-Term Debt to Equity Ratio PHAR|Short-Term Debt to Capital Nektar Corp|Short-Term Debt to Equity Upstream Bio Inc (UPB)|zenasbio.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital IMNM (Immunome)|Gossamer Bio Inc (GOSS) - Current Liabilities to Capital|KalVista Pharmaceuticals Inc - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Septerna Pharma SEPN|PVLA (Pieris Pharmaceuticals) - Short-Term Debt to Equity Ratio|SVRA: Short-Term Loans to Capital Ratio|RIGL (Rigel Pharmaceuticals, Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital AnaptysBio Inc ANAB|Short-Term Debt to Equity Astria Pharma (ATXS)|ENGN - Current Liabilities to Capital|Short-Term Debt to Equity RAPT Therapeutics RAPT|Short-Term Debt to Capital Coefficient Aerovate Therapeutics, Inc. (JBIO)|ACRS: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital KYTX (Kyverna Therapeutics Inc.)|TLSA (Tiziana Life Sciences PLC) - Short-Term Debt to Equity Ratio|CABA: Short-Term Loans to Capital Ratio|VTYX (Ventyx Biosciences) - Short-Term Debt to Capital|THTX: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital AVTX|ELDN - Current Liabilities to Capital|Short-Term Debt to Equity Agenus Inc AGEN|Ratio of Short-Term Indebtedness to Capital CLYM|Zura Bio - Short-Term Debt to Capital|ATYR - Short-Term Debt to Capital|adagene.com (ADAG) - Short-Term Debt to Equity|Current Liabilities to Equity IMA (Ikena Oncology)|STTK (Shattuck Labs Inc) - Short-Term Debt to Capital|Current Liabilities to Capital Equillium Bio EQ|Short-Term Debt to Equity Ratio CNTB (Connect Biopharma)|Short-Term Debt to Capital immunic-therapeutics.com (IMUX)|Atara Bio - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio IFRX (InflaRx NV)|X4 Pharma - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Adicet Bio ACET|CELU: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio inmunebio.com|Short-Term Debt to Equity Barinthus Biotherapeutics plc|Kezar Life Sciences Inc. (KZR) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital SABS|Short-Term Debt to Capital Coefficient Akari Therapeutics, Plc|Enlivex Therapeutics Ltd. - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio QTTB (Q32 Bio Inc)|GOVX - Short-Term Debt to Equity|Current Liabilities to Capital Edesa Biotech Inc|iBio Corp (IBIO) - Short-Term Debt to Equity|CARM - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity XTL Biopharmaceuticals|Bolt Bio - Current Liabilities to Equity|Short-Term Debt to Capital HCWB|APVO (aptevotherapeutics.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital AIM (AIM ImmunoTech Inc.)|Short-Term Debt to Capital Aditxt Inc. ADTX|GRI - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XRTX (xortx.com)|Vyome Holdings (HIND) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Revelation Biosciences Inc|INDP (Indaptus) - Short-Term Debt to Capital|Short-Term Debt to Capital BiondVax Pharmaceuticals|Short-Term Debt to Equity Ratio CALI (CalciMedica, Inc.)|AFMD (affimed.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ALLK (Allakos)|Short-Term Debt to Capital Coefficient HOOKIPA Pharma, Inc. (HOOK)|IGMS - Short-Term Debt to Equity|Ocean Biomedical Corp (OCEA) - Short-Term Debt to Equity Ratio|TC Biopharm (TCBP) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio thirdharmonicbio.com